Risk factor
Very high price volatility
Profitability factor
Very strong margins and returns
About
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E
Buy
Sell